<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01347216</url>
  </required_header>
  <id_info>
    <org_study_id>COMPERA</org_study_id>
    <nct_id>NCT01347216</nct_id>
  </id_info>
  <brief_title>COMPERA / COMPERA-KIDS</brief_title>
  <acronym>COMPERA</acronym>
  <official_title>Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GWT-TUD GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In view of the manifold options for mono- and combination therapy that have now emerged for
      patients with pulmonary (arterial) hypertension (PH/PAH), controlled clinical trials can only
      provide part of the information needed for optimal management. In order to gather adequate
      data on PAH/PH treatment in routine clinical care, the ongoing COMPERA registry prospectively
      documents consecutive patients with newly initiated treatment of PAH/PAH since May 2007. The
      internet-based registry fulfills high quality standards through several measures (planned
      minimum centre contribution of at least 10 patients per year, automated plausibility checks
      of data at entry, queries, monitoring with source data verification in &gt;50% of participating
      centers). It can be applied, among further purposes, for quality assurance: individual
      centers can confidentially compare their results with the combined outcome of other centers
      and the recommendations from guidelines. It is expected that the register contributes to
      optimization of specific drug therapy for PAH and PH.

      Since July 2013, also children of any age can be documented (COMPERA-KIDS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      COMPERA will report current and comprehensive data on

        -  Demographics and clinical course of incident and prevalent PAH and PH patients

        -  Patient outcomes including survival, by subgroup, by treatment strategy and other
           factors

        -  Clinical predictors of short-term and long-term clinical outcomes

        -  Relationship between PAH medications and patient outcomes

        -  Temporal trends in treatments and outcomes for newly diagnosed patients

        -  The state of implementation of current PAH guidelines

        -  Evolving research needs of the PAH community

        -  Patients with PAH associated with congenital heart disease and Eisenmenger physiology
           who do not receive specific drug therapy for PAH (&quot;COMPERA-Eisenmenger&quot;, as stated in
           the amendment dated 23. January 2012).

        -  Children of any age with PH or PAH (all Dana Point groups), as stated in the amendment
           dated 1 June 2013 (&quot;COMPERA-KIDS&quot;).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2007</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients on monotherapy vs combination therapies at baseline and during follow-up (drug utilisation patterns)</measure>
    <time_frame>Up to 10 years after inclusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients in the various Dana Point groups (patient characteristics in PAH and non-PAH pulmonary hypertension groups)</measure>
    <time_frame>Up to 10 years after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Probability of survival in the various Dana Point groups (PAH and non-PAH pulmonary hypertension groups) by Kaplan-Meier estimate</measure>
    <time_frame>Up to 10 years after inclusion</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">8000</enrollment>
  <condition>Pulmonary Arterial Hypertension (PAH)</condition>
  <condition>Pulmonary Hypertension (PH)</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with any manifestation of pulmonary hypertension
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All age groups (amendment dated 1 June 2013)

          -  Written informed consent

          -  Pulmonary hypertension (PH) of either

               -  PAH: idiopathic form (IPAH) or

               -  PAH associated with connective tissue diseases (PAH-CTD), with congenital heart
                  defects (PAH-CHD), with HIV infection (PAH-HIV), or the portopulmonary form

               -  Chronic thromboembolic PH (CTEPH)

               -  PH in left heart diseases (with isolated diastolic dysfunction; with systolic
                  dysfunction, other)

               -  PH in pulmonary disease (chronic obstructive pulmonary disease; interstitial
                  fibrosis, etc.)

               -  &quot;Relative PH&quot; in CHD after cavopulmonary anastomosis or Fontan-type surgery, even
                  without the classical pulmonary pressure criteria of PH.

          -  Newly initiated (i.e. a maximum of 3 months before documentation for the first time)
             therapy with endothelin receptor antagonists (ERA), phoshodiesterase-5 (PDE-5)
             inhibitors, soluble guanylate cyclase (sGC) stimulators or prostacyclins in mono- or
             combination therapy.

        Exceptions: PAH-CHD patients can be included on maintenance or newly initiated PAH therapy
        (3-month rule dose not apply).

        PAH-CHD patients with severe pulmonary vascular disease (e.g. Eisenmenger physiology)
        irrespective of treatment with any PAH drugs are eligible for inclusion, too.

        Exclusion Criteria:

          -  Patients on maintenance therapy, i.e. previous treatment with any ERA/ PDE-5
             inhibitor/prostacyclin/sGC stimulator drug longer than 3 months before documentation
             for the first time (exception: PAH-CHD patients).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wilhelm Kirch, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Institute for Clinical Pharmacology, Medical Faculty, Technical University Dresden, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marius M Hoeper, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pulmonology, Medical School Hannover, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ardeschir Ghofrani, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Lung Centre, Giessen, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marion Delcroix, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Dept of Pneumology, University Leuven, Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dario Vizza, MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Cardiovascular and Respiratory Sciences, University La Sapienza, Rome, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Pittrow, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Institute for Clinical Pharmacoloy, Medical Faculty, Technical University Dresden, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian Opitz, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Cardiology, DRK-Kliniken Berlin, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Oliver Distler, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Department for Rheumatology, University Hospital Zurich, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harald Kaemmerer, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>German Heart Centre, Munich, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Simon R Gibbs, MD</last_name>
    <role>Study Director</role>
    <affiliation>Imperial College London, UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephan Rosenkranz, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Heart Centre, Cologne</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ekkehard Grünig, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Centre for Pulmonary Hypertension at Thoraxclinic Heidelberg, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthias Gorenflo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. Paed. Cardiol./Congenital Cardiology, Heidelberg University Medical Centre, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Pittrow, MD, PhD.</last_name>
    <phone>+49351458</phone>
    <phone_ext>2815</phone_ext>
    <email>david.pittrow@mailbox.tu-dresden.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marius Hoeper, MD, PhD</last_name>
    <phone>+49511532</phone>
    <phone_ext>3537</phone_ext>
    <email>Hoeper.Marius@mh-hannover.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dept. of Pneumology, University</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marion Delcroix, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Marion Delcroix, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DRK-Klinikum Köpenick</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Opitz, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Christian Opitz, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lung Centre, University of Giessen</name>
      <address>
        <city>Giessen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ardeschir Ghofrani, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Ardeschir Ghofrani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Melanie Thamm, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Pulmology; Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marius M Hoeper</last_name>
    </contact>
    <investigator>
      <last_name>Marius M Hoeper, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karen Olsson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>German Heart Centre</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harald Kaemmerer, MD,. PhD</last_name>
    </contact>
    <investigator>
      <last_name>Harald Kaemmerer, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sean Gaine, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Sean Gaine, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Cardiovascular and Respiratory Sciences, University La Sapienza</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dario Vizza, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Dario Vizza, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. for Rheumatology, University Hospital</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliver Distler, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Oliver Distler, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Pittrow D, Ghofrani HA, Opitz CF, Huscher D, Hoeper MM. [International, prospective register for the documentation of first-line and maintenance therapy in patients with pulmonary hypertension (CompERA-XL)]. Dtsch Med Wochenschr. 2009 Aug;134 Suppl 5:S173-5. doi: 10.1055/s-0029-1225318. Epub 2009 Aug 28. Review. German.</citation>
    <PMID>19718609</PMID>
  </reference>
  <results_reference>
    <citation>Hoeper MM, Huscher D, Ghofrani HA, Delcroix M, Distler O, Schweiger C, Grunig E, Staehler G, Rosenkranz S, Halank M, Held M, Grohé C, Lange TJ, Behr J, Klose H, Wilkens H, Filusch A, Germann M, Ewert R, Seyfarth HJ, Olsson KM, Opitz CF, Gaine SP, Vizza CD, Vonk-Noordegraaf A, Kaemmerer H, Gibbs JS, Pittrow D. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol. 2013 Sep 30;168(2):871-80. doi: 10.1016/j.ijcard.2012.10.026. Epub 2012 Nov 17.</citation>
    <PMID>23164592</PMID>
  </results_reference>
  <results_reference>
    <citation>Olsson KM, Delcroix M, Ghofrani HA, Tiede H, Huscher D, Speich R, Grünig E, Staehler G, Rosenkranz S, Halank M, Held M, Lange TJ, Behr J, Klose H, Claussen M, Ewert R, Opitz CF, Vizza CD, Scelsi L, Vonk-Noordegraaf A, Kaemmerer H, Gibbs JS, Coghlan G, Pepke-Zaba J, Schulz U, Gorenflo M, Pittrow D, Hoeper MM. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation. 2014 Jan 7;129(1):57-65. doi: 10.1161/CIRCULATIONAHA.113.004526. Epub 2013 Sep 30.</citation>
    <PMID>24081973</PMID>
  </results_reference>
  <results_reference>
    <citation>Hoeper MM, Behr J, Held M, Grunig E, Vizza CD, Vonk-Noordegraaf A, Lange TJ, Claussen M, Grohé C, Klose H, Olsson KM, Zelniker T, Neurohr C, Distler O, Wirtz H, Opitz C, Huscher D, Pittrow D, Gibbs JS. Pulmonary Hypertension in Patients with Chronic Fibrosing Idiopathic Interstitial Pneumonias. PLoS One. 2015 Dec 2;10(12):e0141911. doi: 10.1371/journal.pone.0141911. eCollection 2015.</citation>
    <PMID>26630396</PMID>
  </results_reference>
  <results_reference>
    <citation>Hoeper MM, Huscher D, Pittrow D. Incidence and prevalence of pulmonary arterial hypertension in Germany. Int J Cardiol. 2016 Jan 15;203:612-3. doi: 10.1016/j.ijcard.2015.11.001. Epub 2015 Nov 9.</citation>
    <PMID>26580339</PMID>
  </results_reference>
  <results_reference>
    <citation>Opitz CF, Hoeper MM, Gibbs JS, Kaemmerer H, Pepke-Zaba J, Coghlan JG, Scelsi L, D'Alto M, Olsson KM, Ulrich S, Scholtz W, Schulz U, Grünig E, Vizza CD, Staehler G, Bruch L, Huscher D, Pittrow D, Rosenkranz S. Pre-Capillary, Combined, and Post-Capillary Pulmonary Hypertension: A Pathophysiological Continuum. J Am Coll Cardiol. 2016 Jul 26;68(4):368-78. doi: 10.1016/j.jacc.2016.05.047.</citation>
    <PMID>27443433</PMID>
  </results_reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2011</study_first_submitted>
  <study_first_submitted_qc>May 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2011</study_first_posted>
  <last_update_submitted>July 31, 2017</last_update_submitted>
  <last_update_submitted_qc>July 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug treatment</keyword>
  <keyword>Treatment pathways</keyword>
  <keyword>Clinical routine</keyword>
  <keyword>Registry</keyword>
  <keyword>Treatment outcomes</keyword>
  <keyword>Endothelin receptor antagonist</keyword>
  <keyword>Phosphodiesterase-V inhibitor</keyword>
  <keyword>Prostanoid</keyword>
  <keyword>Sildenafil</keyword>
  <keyword>Bosentan</keyword>
  <keyword>Macitentan</keyword>
  <keyword>Sitaxentan</keyword>
  <keyword>Ambrisentan</keyword>
  <keyword>Imatinib</keyword>
  <keyword>Epoprostenol</keyword>
  <keyword>Treprostinil</keyword>
  <keyword>Iloprost</keyword>
  <keyword>Infusion pump</keyword>
  <keyword>Riociguat</keyword>
  <keyword>soluble guanylate cyclase stimulator</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Patient-related outcomes</keyword>
  <keyword>Economic model</keyword>
  <keyword>Adverse event</keyword>
  <keyword>Safety</keyword>
  <keyword>Combination therapy</keyword>
  <keyword>Internet</keyword>
  <keyword>Europe</keyword>
  <keyword>Australia</keyword>
  <keyword>Japan</keyword>
  <keyword>Eisenmenger</keyword>
  <keyword>Adults</keyword>
  <keyword>Children</keyword>
  <keyword>Selexipag</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endothelin Receptor Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data sharing has not been planned.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

